<DOC>
	<DOCNO>NCT02789137</DOCNO>
	<brief_summary>The purpose study know quality life patient metastatic renal cell carcinoma treat sunitinib , pazopanib sorafenib , suffer fatigue hand-foot syndrome , personal inter-variability , explore measure take term everyday lifestyle treatment mitigate cure side effect affect patient .</brief_summary>
	<brief_title>Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor First-Line Treatment</brief_title>
	<detailed_description>Prospective , multicentre , observational study patient metastatic renal cell carcinoma ( mRCC ) receive tyrosine kinase inhibitor first-line treatment accord routine clinical practice , design evaluate incidence fatigue hand-foot syndrome order determine affect baseline characteristic patient his/her disease ( age , gender , baseline status , tumour histology , etc . ) patient 's lifestyle side effect develop . An exploratory analysis perform measure clinician may adopt improve patient ' quality life regard daytime nap , medication administration time , off-treatment period , dose reduction treatment break .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients ≥ 18 year old diagnose metastatic RCC , investigator 's opinion , candidate start firstline treatment tyrosine kinase inhibitor accord routine clinical practice . Patients contraindication treatment . Baseline ECOG ≤ 2 . Patients able give inform consent without need legal representative . Committed patient able complete quality life questionnaires patient diary without need legal representative . Patients candidate firstline treatment tyrosine kinase inhibitor . Patients receive treatment secondline subsequent therapy . Untreated hypothyroidism . Untreated severe anaemia . Pregnancy breastfeed . Myocardial infarction cerebrovascular accident ( CVA ) within last 6 month . Severe hepatic impairment . Concomitant use potent inhibitor inducer interact hepatic cytochrome CYP3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic renal cell carcinoma</keyword>
</DOC>